Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer Cells

Purpose: HDAC inhibitors (HDACIs) have been shown to inhibit cancer cell proliferation, stimulate apoptosis, and induce cell cycle arrest. Our purpose was to investigate the antiproliferative effects of the HDACIs [suberoyl anilide bishydroxamine, valproic acid (VPA), trichostatin A, and sodium butyrate] against six endometrial cancer cell lines. Experimental Design: Endometrial cancer cells were treated with a variety of HDACIs, and the effect on cell growth, cell cycle, and apoptosis was measured. The ability of VPA to inhibit the growth of endometrial tumors growing in immunodeficient mice was also assessed. Results: Clonogenic assays showed that all cancer cell lines were sensitive to the growth inhibitory effect of HDACIs. Cell cycle analysis indicated that treatment with HDACIs decreased the proportion of cells in S phase and increased the proportion of cells in the G0-G1 and/or G2-M phases of the cell cycle. Terminal deoxynucleotidyl transferase-mediated nick end labeling assays showed that HDACIs induced apoptosis. This was concomitant with altered expression of genes related to malignant phenotype, including an increase in p21Waf1, p27Kip7, and E-cadherin and a decrease in Bcl-2 and cyclin-D1 and -D2. Chromatin immunoprecipitation analysis revealed a remarkable increase in levels of acetylated histones associated with the p21 promoter after suberoyl anilide bishydroxamine treatment. In nude mice experiments, VPA inhibited significantly human uterine tumor growth without toxic side effects. Conclusions: These results suggest that HDACIs are effective in inhibiting growth of endometrial cancer cells in vitro and in nude mice, without toxic side effects. The findings raise the possibility that HDACIs may prove particularly effective in treatment of endometrial cancers.

[1]  J. Said,et al.  Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. , 2003, Journal of the National Cancer Institute.

[2]  J. Benda,et al.  Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.

[3]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[4]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[5]  S. Horiuchi,et al.  Sodium butyrate induces growth arrest and senescence‐like phenotypes in gynecologic cancer cells , 2001, International journal of cancer.

[6]  R C Coombes,et al.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  J. Davie,et al.  Rapid Induction of Histone Hyperacetylation and Cellular Differentiation in Human Breast Tumor Cell Lines following Degradation of Histone Deacetylase-1* , 2000, The Journal of Biological Chemistry.

[8]  W. D. Cress,et al.  Inhibition of Mitogenesis in Balb/c-3T3 Cells by Trichostatin A , 2000, The Journal of Biological Chemistry.

[9]  M. Yoshida,et al.  Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. , 2000, The Journal of antibiotics.

[10]  R. Dahiya,et al.  Inactivation of the human androgen receptor gene is associated with CpG hypermethylation in uterine endometrial cancer , 2000, Molecular carcinogenesis.

[11]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Herman,et al.  Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. , 2000, Cancer research.

[13]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[14]  S. Baylin,et al.  DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci , 2000, Nature Genetics.

[15]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[16]  D. Cohen,et al.  Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects* , 1999, The Journal of Biological Chemistry.

[17]  A. Riegel,et al.  Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels: an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter. , 1999, Experimental cell research.

[18]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[19]  T. Naoe,et al.  Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy , 1999, Leukemia.

[20]  H. Huang,et al.  Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. , 1999, Cancer research.

[21]  R. Alvarez,et al.  Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Johnson,et al.  Cyclins and cell cycle checkpoints. , 1999, Annual review of pharmacology and toxicology.

[23]  S. Ōmura,et al.  Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. , 1999, Biochemical and biophysical research communications.

[24]  S. Jones,et al.  Histone deacetylase inhibitors as potential anti-skin cancer agents. , 1999, Cancer research.

[25]  S. Minucci,et al.  Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO , 1998, Molecular and Cellular Biology.

[26]  P. Pandolfi,et al.  Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. , 1998, Journal of the National Cancer Institute.

[27]  R. Evans,et al.  The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. , 1998, Nucleic acids research.

[28]  T. Hoshino,et al.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Faller,et al.  Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[30]  Chi-Wai Wong,et al.  Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein , 1998, Oncogene.

[31]  S. Schreiber,et al.  Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Wen‐Ming Yang,et al.  Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression , 1997, Cell.

[33]  J. Galmiche,et al.  Butyrate stimulates cyclin D and p21 and inhibits cyclin-dependent kinase 2 expression in HT-29 colonic epithelial cells. , 1997, Biochemical and biophysical research communications.

[34]  F. Lallemand,et al.  Direct inhibition of the expression of cyclin D1 gene by sodium butyrate. , 1996, Biochemical and biophysical research communications.

[35]  D. Mutch,et al.  A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[36]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[37]  S. Horinouchi,et al.  Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  Alan P. Wolffe,et al.  Transcription: In tune with the histones , 1994, Cell.

[39]  G. Felsenfeld,et al.  Chromatin as an essential part of the transcriptional mechanim , 1992, Nature.

[40]  M. Takeichi,et al.  Cadherin cell adhesion receptors as a morphogenetic regulator. , 1991, Science.

[41]  M. Yoshida,et al.  Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. , 1990, The Journal of antibiotics.

[42]  S. Freytag.  Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1 , 1988, Molecular and cellular biology.

[43]  J. Simiand,et al.  Mechanism of anticonvulsant action of valproate , 1982, Progress in Neurobiology.

[44]  Douglas,et al.  Butyrate-induced G , Arrest Results from p 21-independent Disruption of Retinoblastoma Protein-mediated Signals 1 , 2005 .

[45]  C. Van Lint,et al.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.

[46]  C. Young,et al.  Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities , 1995, Journal of cellular biochemistry. Supplement.